ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Cellectis SA

Cellectis SA (CLLS)

1.8899
-0.0741
( -3.77% )
Updated: 13:14:16

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.8899
Bid
1.87
Ask
1.88
Volume
90,381
1.85 Day's Range 1.93
0.962777 52 Week Range 3.7735
Market Cap
Previous Close
1.964
Open
1.85
Last Trade
750
@
1.8899
Last Trade Time
13:12:39
Financial Volume
$ 171,698
VWAP
1.8997
Average Volume (3m)
54,932
Shares Outstanding
71,751,201
Dividend Yield
-
PE Ratio
-1.22
Earnings Per Share (EPS)
-1.41
Revenue
9.2M
Net Profit
-101.06M

About Cellectis SA

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various unive... Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Paris, Paris, Fra
Founded
1970
Cellectis SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CLLS. The last closing price for Cellectis was $1.96. Over the last year, Cellectis shares have traded in a share price range of $ 0.962777 to $ 3.7735.

Cellectis currently has 71,751,201 shares outstanding. The market capitalization of Cellectis is $123.41 million. Cellectis has a price to earnings ratio (PE ratio) of -1.22.

CLLS Latest News

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

Cellectis Reports Financial Results for First Quarter 2024

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3501-15.62946428572.242.31.85795902.08893812CS
4-0.9701-33.91958041962.862.91261.85433352.35801282CS
12-0.7201-27.59003831422.613.381.85549322.773713CS
26-1.5601-45.22028985513.453.731.85520792.84427777CS
52-0.0901-4.550505050511.983.77350.9627775164772.71180842CS
156-12.9101-87.230405405414.816.450.9627772790414.11421312CS
260-12.5701-86.930152143814.4634.710.9627772533469.4082418CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.7151
(137.57%)
294.97M
NXLNexalin Technologies Inc
$ 2.14
(94.55%)
44.32M
SHCRSharecare Inc
$ 1.365
(76.27%)
35.78M
SPECSpectaire Holdings Inc
$ 0.543
(59.71%)
59.4M
MINMMinim Inc
$ 3.83
(33.92%)
42.04M
KAVLKaival Brands Innovations Group Inc
$ 1.475
(-48.61%)
3.35M
FLFVFeutune Light Acquisition Corporation
$ 5.01
(-40.57%)
43.63k
PBMPsyence Biomedical Ltd
$ 0.4039
(-32.68%)
2.28M
RELIReliance Global Group Inc
$ 0.464
(-23.17%)
7.65M
IVDAIveda Solutions Inc
$ 0.451
(-19.82%)
54.16k
NVDANVIDIA Corporation
$ 127.505
(-2.50%)
306.6M
AREBAmerican Rebel Holdings Inc
$ 0.7146
(137.41%)
294.98M
CRKNCrown Electrokinetics Corporation
$ 0.0408
(-18.40%)
139.12M
NKLANikola Corporation
$ 0.3753
(13.87%)
128.36M
ASTIAscent Solar Technologies Inc
$ 0.1114
(3.24%)
114.61M

CLLS Discussion

View Posts
PonkenPlonken PonkenPlonken 3 weeks ago
Look who wants to be a part of this... Many many partners and very real biobucks.
AZN increasing their stake like this - validates their science.
👍️0
Monksdream Monksdream 4 weeks ago
CLLS under $3
👍️0
Monksdream Monksdream 2 months ago
CLLS under $3
👍️0
Monksdream Monksdream 7 months ago
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023. The additional investment will be made by way of subscription of 10,000,000 “class A” convertible preferred shares and 18,000,000 “class B” convertible preferred shares, in each case at a price of $5.00 per share (the “Additional Investment”).
👍️0
Money hunt Money hunt 8 months ago
Still on fire 🔥 Big deal in the works
👍️0
Money hunt Money hunt 8 months ago
Popping pills and buying shares and flying everywhere dudes !!!
👍️0
TheFinalCD TheFinalCD 8 months ago
2.99 on sale
👍️0
TheFinalCD TheFinalCD 8 months ago
i did just buy 2k @ 2.48 then it had a nice pop

more green is good
👍️0
TheFinalCD TheFinalCD 8 months ago
yeah they had me cough my shares back up, for a small profit

they=algos


first off they gapped it up way too high in the 1st place, so its hard to go in with size when the previous close was .97

they do this BS all the time to retail

when news hits you have no chance of buying in low, they rail it up so fast, before you even get done reading the news

then they short it back until it finds support or they decide to change directions

as a day trader Im so sick of this routine
👍️0
Jess070283 Jess070283 8 months ago
Next stop $4+ IMO…
👍️0
MetaMonster MetaMonster 8 months ago
Not with FDA green light
👍️0
zj3001 zj3001 8 months ago
The $80m upfront for 22% equity suggest the market cap should be about $363m + other assets.
👍️0
jchords jchords 8 months ago
Think it’ll be a while?
👍️0
MetaMonster MetaMonster 8 months ago
Huge news CLLS Rnaz is next
👍️0
Monksdream Monksdream 8 months ago
Long day ahead
👍️0
TheFinalCD TheFinalCD 8 months ago
NICE NEWS

https://www.globenewswire.com/news-release/2023/11/01/2770788/0/en/Cellectis-Announces-Strategic-Collaboration-and-Investment-Agreements-with-AstraZeneca.html

https://dilutiontracker.com/app/search/CLLS
👍️0
Monksdream Monksdream 8 months ago
Will it grow legs after 9:30
Will it trend north for days, weeks, months
👍️0
tw0122 tw0122 8 months ago
straZeneca to Invest $245 Million in Deal With Cellectis

Source: Dow Jones News
By Ben Otto


British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics in oncology, immunology and rare diseases.

AstraZeneca said Wednesday that it will initially make a $105 million payment to Paris-based Cellectis in the fourth quarter, comprising an $80 million equity investment, for a 22% stake in the company, and $25 million in cash.

AstraZeneca plans to make a further $140 million equity investment, subject to regulatory and other approvals, with a closing in early 2024, taking its total stake in Cellectis to 44%.

AstraZeneca said it plans to leverage Cellectis's gene-editing technologies and manufacturing capabilities to design novel cell and gene therapy products.

Cellectis will be eligible to receive an investigational new drug option fee and various milestone payments ranging from $70 million to up to $220 million for each of 10 candidate products, plus tiered royalties, AstraZeneca said.

AstraZeneca will retain an option for an exclusive license for the products developed under the research collaboration agreement.

👍️0
Monksdream Monksdream 9 months ago
CLLS under $2
👍️0
Monksdream Monksdream 11 months ago
Cellectis SA NASDAQ: CLLS

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
👍️0
Frankestin Frankestin 1 year ago
https://www.cellectis.com/uploads/files/051123_PosterASGCT2023_BAOa.pdf
https://www.cellectis.com/uploads/files/UCART123_AMELI-01_Phase_1_Oral_Presentation_ASGCT_2023_Final_Upload.pdf
👍️0
Frankestin Frankestin 1 year ago
file:///C:/Users/bozh/Downloads/UCART123_AMELI-01_Phase_1_Oral_Presentation_ASGCT_2023_Final_Upload.pdf
file:///C:/Users/bozh/Downloads/051123_PosterASGCT2023_BAOa.pdf

Evidence of UCART123 anti-tumor activity was observed in four patients out of fifteen at DL2 or above with best overall responses in the FCA arm. Two out of eight patients (25%) at DL2 in the FCA arm achieved meaningful response: * A patient who failed five prior lines of therapy experienced a durable minimal residual disease (MRD) negative complete response (CR) with full count recovery at Day 56 that continues beyond one year.

* A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.

The preliminary data show that adding alemtuzumab to the FC LD regimen was associated with sustained lymphodepletion and significantly higher UCART123 cell expansion, which correlated with improved anti-tumor activity.

Patient Enrollment in a 2-Dose Regimen Arm

Overall, these preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. Based on observed UCART123 expansion patterns and cytokine profiles, pursuant to an amended protocol, a second dose of UCART123 is given after 10-14 days to allow for additional UCART123 expansion and clinical activity without the use of additional lymphodepletion. The UCART123 cell expansion from the second dose of UCART123, in the setting of reduced disease burden, is expected to be safe and allow for clearance of residual disease.

“These clinically meaningful preliminary data from the AMELI-01 study are very encouraging for patients and for the future of allogeneic CART-cell therapy. AML is a disease with an urgent need for alternative treatment options for patients, and we are excited to be moving the study forward,” said Dr. Mark Frattini, M.D., Ph.D., Chief Medical Officer at Cellectis. “We have now implemented a two-dose regimen arm for our AMELI-01 trial and we look forward to sharing future updates as they become available.”
👍️0
Frankestin Frankestin 1 year ago
grabbed a handful yesterday.
I wonder if tomorrow they surprise us a little?
👍️0
Frankestin Frankestin 1 year ago
https://ih.advfn.com/stock-market/NASDAQ/cellectis-CLLS/stock-news/83912184/cellectis-announces-withdrawal-of-follow-on-offeri
Seems like it's better now...
I hope they sell them to pfizer
👍️0
Frankestin Frankestin 2 years ago
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

* UCART22: ANTI-TUMOR ACTIVITY OBSERVED IN 60% (N=3) OF PATIENTS AT DL3 USING FCA LYMPHODEPLETION
* AMELI-01 STUDY (EVALUATING UCART123) NOW ENROLLING PATIENTS IN A TWO-DOSE REGIMEN ARM AT DL2
* UCART123: 25% (N=2) OF PATIENTS AT DL2 IN FCA ARM ACHIEVED MEANINGFUL RESPONSE
* NEXT DATA SET IS EXPECTED TO BE RELEASED IN 2023
* UCART123: ONE PATIENT EXPERIENCED A DURABLE MINIMAL RESIDUAL DISEASE (MRD)-NEGATIVE COMPLETE RESPONSE THAT CONTINUES BEYOND 12 MONTHS


dry hands still sell
👍️0
Frankestin Frankestin 2 years ago
will there be something interesting?

November 4(th), 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities.

he is quite slapped in the face and someone sees him for $ 2

in a while they will have to load money somehow ...
apparently they refused to bid when she was high
👍️0
Frankestin Frankestin 2 years ago
also interesting here!
Yes, yes
👍️0
whytestocks whytestocks 5 years ago
News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates

Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline Manufacturing to take place at Lonza’s GMP site in Geleen, Netherlands Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a cl...

Read the whole news CLLS - Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates
👍️0
n4807g n4807g 6 years ago
J.P Morgan Healthcare conference presentation is worth listening to. At current valuation CLLS is undervalued.....very undervalued.
👍️0
n4807g n4807g 7 years ago
Not uncommon with new therapies. Much too early to draw any conclusions about UCART123. The trial will most likely resume with recommended adjustments.
👍️0
Avispa Avispa 7 years ago
https://seekingalpha.com/news/3293436-cellectis-29-percent-premarket-fda-hold-studies-ucart123-fatality
👍️0
north40000 north40000 7 years ago
FDA imposes clinical hold on CART-123.... patient death.
👍️0
n4807g n4807g 7 years ago
with the GILD acquisition of KITE the potential for CAR-T, and more specifically Alogeneic CAR-T increases dramatically. FWIW CLLS is one of the leaders (if not the leader) in this sphere. Additionally, their partnership with Pfizer opens tantalizing possibilities for the future if the technology, and their therapies prove valid.

Something worth reading:

http://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_cellectis_enter_into_global_strategic_cancer_immunotherapy_collaboration

and of particular interest.....

Under the terms of the agreement, Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets selected by Pfizer. Both companies will work together on preclinical research and Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets. In addition, the agreement provides for a total of twelve targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of CAR-T therapeutics for the Cellectis-selected targets. Pfizer has right of first refusal to the four Cellectis-selected targets.

I am long CLLS and accumulating shares.
👍️0
u508 u508 7 years ago
Cellectis’CAR-T cells act as “universal donor” cells.

Other CAR-T therapies must remove immune system cells from a patient’s blood. Then these cells have to be worked on in a lab. They must be multiplied. Genes must be edited. Then the cells have to be reinfused into the patient to do their work.

Each patient is a one-off therapeutic product! Each dose will cost tens of thousands of dollars just to make.

Cellectis, however, has created a line of CAR-T cells that can work in anyone.
👍️0
Sixman Sixman 7 years ago
I read that too. The CART Space is interesting and I understand CLLS is developing a method that would allow more treatment of multiple types of cancer?

It's showing good signs of strength.
👍️0
u508 u508 7 years ago
interest due to successful treatment of little girl using their "universal" CAR-T cells. Wish I had cash to buy more shares but I'm a small investor - $20+ is expensive for me....
👍️0
Sixman Sixman 7 years ago
Lots of interest last few days. Anyone out there following CLLS?
👍️0
lucmariepierre lucmariepierre 8 years ago
Sincerely i have no idea
It was 45 dollars
Now it is 20 dollars

This stock is unbalanced i think

Why so high or so low ?
👍️0
murocman murocman 8 years ago
Anyone have any idea on when the first results from the Ph I trial at UCL might be published. All I can find is the the trial is open label and is non-comparative---no information on number of patients or time to completion.

GLTA,

Murocman
👍️0
biscotte biscotte 8 years ago
CNBC : CLLS ==> 100$ ! ???



👍️0
north40000 north40000 8 years ago
http://in.reuters.com/article/us-health-celltherapy-idINKCN0XX1F7?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29

"A second baby with aggressive leukaemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, remains in remission, the French biotech firm said.

Cellectis shares jumped 14 percent following Friday's news.

The first human use of the company's cell therapy made headlines worldwide in November when one-year-old Layla was cleared of previously incurable leukaemia at Britain's Great Ormond Street Hospital (GOSH).

Details of the latest compassionate care case, also treated at GOSH, were presented at the American Society of Gene & Cell Therapy annual meeting in Washington.

The so-called UCART19 injection works by adding new genes to healthy donated immune cells known as T-cells, which arm them against leukaemia.[more]
👍️0
venturecapp venturecapp 8 years ago
Post-Holiday Action: Movers and Shakers in Biotech - article mentions Cellectis

http://marketexclusive.com/post-holiday-action-movers-and-shakers-in-biotech/1207/
👍️0
MrPoppaGeorgeo MrPoppaGeorgeo 9 years ago
Et like da (I) not da (o)(o)
👍️0
~Angel~ ~Angel~ 9 years ago
vroom
👍️0
MrPoppaGeorgeo MrPoppaGeorgeo 9 years ago
CLLS has the V power (I)
👍️0
MrPoppaGeorgeo MrPoppaGeorgeo 9 years ago
Boooom CLLS was just at $24
👍️0
cantgetmyname cantgetmyname 9 years ago
http://www.reuters.com/article/2015/11/05/us-health-leukaemia-cellectis-idUSKCN0SU2PO20151105
👍️0
MrPoppaGeorgeo MrPoppaGeorgeo 9 years ago
Nice, this moves along with JUNO..it's should be back in the 40's soon
👍️0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 9 years ago
I just go in this 37 it's a volatility squeeze look at the Bollinger bands. Where do you see this headed? Volume is picking up to.
👍️0
MrPoppaGeorgeo MrPoppaGeorgeo 9 years ago
CLLS news http://ih.advfn.com/p.php?pid=nmona&article=67231007
👍️0

Your Recent History

Delayed Upgrade Clock